Therefore, under the diagnosis of presumed HER2-positive occult breast cancer, the patient received 4 courses of trastuzumab, pertuzumab, and docetaxel chemotherapy as a primary systemic therapy and got marked shrinkage of the enlarged lymph nodes (Fig. 2B) with normalization of the elevated CEA level. The gene discussed is ERBB2; the disease is breast cancer.